Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

AZD4954

Phase 1Small molecule

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

DyslipidemiaRecruiting

DyslipidemiaPhase 1

Recruiting

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Dyslipidemia

NCT06980428

Clinical

Trials by Indication[1]

Dyslipidemia1 trial

A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4954 Following Single and Multiple Ascending Dose Administration to Healthy Participants With or Without Elevated Lp(a) Levels, and Participants With Dyslipidemia

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT06980428·136 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AZD4954. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD4954 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD4954. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AstraZeneca

Related News